- Business Wire•12 hours agoAgilent Technologies Receives Expanded FDA Approval for Use of Dako PD-L1 IHC 22C3 pharmDx Companion Diagnostic in Non-Small Cell Lung Cancer (NSCLC)
Agilent Technologies Inc. today announced that its Dako PD-L1 IHC 22C3 pharmDx now has an expanded label approved by the U.S. Food and Drug Administration for use in determining PD-L1 expression status to inform treatment in metastatic non-small cell lung cancer with KEYTRUDA® .
- Zacks•4 days ago
PayPal Holdings, Inc. (PYPL) delivered strong third-quarter 2016 results, surpassing the Zacks Consensus Estimate on both counts.
- Business Wire•5 days ago
Agilent Technologies Inc. today launched a comprehensive offering of pooled CRISPR libraries for functional genomics. SureGuide harnesses Agilent’s industry-leading oligonucleotide synthesis platform to create CRISPR guide libraries, which are a critical component of the CRISPR/Cas genome editing system.
Agilent Technologies, Inc. (A)
NYSE - NYSE Real Time Price. Currency in USD
|Bid||43.01 x 200|
|Ask||48.00 x 500|
|Day's Range||45.64 - 45.95|
|52wk Range||34.15 - 48.63|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||31.80|
|Avg Vol (3m)||1,826,336|
|Dividend & Yield||0.46 (1.01%)|